INS and Hypoglycemia: Recent studies suggest that GLP-1 receptor agonists can replace rapid-acting insulin in basal insulin therapy, with cost-saving benefits, effective glycemic control, and reduced risk of weight gain and hypoglycemia in patients with T2D uncontrolled on conventional basal insulin regimen [81,82,83,84,85].